Answers are grounded in this paper and cite their sources.
Nondestructive, post-exposure monitoring of latent photoresist patterns remains challenging because conventional metrology relies on post-development inspection, making it difficult to attribute deviations to exposure conditions. We propose an autofluorescence-imaging-based monitoring method that operates immediately after UV exposure, using excitation wavelengths spectrally separated from the exposure wavelength, and establish its performance as a measurement. To identify a suitable monitoring wavelength, latent patterns were imaged at four excitation wavelengths. Among the wavelengths tested, 561 nm provided the most stable latent-pattern signal, with only a −3.1 % change after 30 s of continuous excitation, whereas shorter-wavelength excitation caused unintended additional exposure or substantial photobleaching. The autofluorescence contrast increased nonlinearly with exposure dose and gradually approached saturation, as described by a model derived from depth-integrated photochemical conversion. Inverting the fitted response estimated the delivered dose with 6–11 % RMS error (leave-one-out), and retained sensitivity above the dose to clear, where the developed topography saturated and post-development inspection became insensitive to over-dose. In two independently conducted exposure experiments, no systematic monitoring-induced change in the developed geometry was detected, and the minimum detectable dose was 9.7 mJ/cm² at 3σ. This label-free approach enables pre-development latent-pattern imaging and quantitative dose monitoring for microscale maskless lithography and process development.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: